Company profile

Insmed Incorporated

Pipeline9 assets

BrensocatibBRINSUPRI / DPP1 / Small Molecule / Respiratory / Immunology
Non-Cystic Fibrosis Bronchiectasis (NCFB)MarketedActiveUSEUHidradenitis SuppurativaPhase 2ActiveGlobal
Amikacin Liposome Inhalation SuspensionARIKAYCE / Bacterial 30S ribosomal subunit / Liposomal Inhalation Suspension / Respiratory / Infectious Disease
Refractory Mycobacterium avium complex (MAC) Lung DiseaseMarketedActiveUSEUJPMAC Lung Disease (Label Expansion)Phase 3ActiveGlobal
Treprostinil Palmitil Inhalation PowderTPIP / Prostacyclin receptor / Inhalation Powder / Respiratory / Pulmonary
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)Phase 3ActiveGlobalPulmonary Arterial Hypertension (PAH)Phase 3ActiveGlobalProgressive Pulmonary Fibrosis (PPF)Phase 3 PlannedActiveGlobal
INS1148INS1148 / Stem Cell Factor SCF248 / Monoclonal Antibody / Respiratory / Immunology
Interstitial Lung Disease (ILD)Phase 2ActiveGlobalModerate-to-severe asthmaPhase 2ActiveGlobal
INS1033INS1033 / Unknown / Unknown / Immunology & Inflammation
Inflammatory diseasesPreclinicalActiveGlobal
Intrathecal gene therapy for DMDDystrophin / Gene Therapy / Neurology / Rare Disease
Duchenne Muscular Dystrophy (DMD)Phase 1ActiveGlobal
INS1202INS1202 / Unknown / Unknown / Neurology / Rare Disease
Amyotrophic Lateral Sclerosis (ALS)Phase 1ActiveGlobal
Stargardt Disease Gene TherapyUnknown / Gene Therapy / Ophthalmology / Rare Disease
Stargardt DiseasePreclinicalActiveGlobal
Next-Gen DPP1 InhibitorsDPP1 / Small Molecule / Immunology & Inflammation
UndisclosedPreclinicalActiveGlobal